drugset / Trial / NCT01789398

Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)

NCT01789398

Phase 3 Completed 51 enrolled Bioprojet
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multicentric international phase III, double blind randomized study assessing efficacy and safety in parallel group of BF2.649 (pitolisant) compared to placebo in add-on to sodium oxybate of narcoleptic patients with residual Excessive Daytime Sleepiness (EDS) during 8 weeks

Timeline

Start
2012-09
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Pitolisant Small molecule 5 mg Oral
Subject Pitolisant Small molecule 10 mg Oral
Subject Pitolisant Small molecule 20 mg Oral
Subject Pitolisant Small molecule 40 mg Oral

Indications